v3.25.1
Segments - Schedule of Reportable Segment Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Stock compensation expense $ 3,588 $ 2,247
Interest income, net (3,602) (4,748)
Net loss 47,911 29,065
Segment [Member]    
Segment Reporting Information [Line Items]    
Chronic cough in IPF clinical trial expense 14,615 5,867
Refractory chronic cough clinical trial expense 6,042 2,383
Other clinical trials and studies [1] 4,313 4,410
Clinical trial material 3,235 2,216
Other clinical development expenses [2] 4,008 3,154
Employee compensation (excluding stock compensation expense) 9,265 7,883
Stock compensation expense 3,588 2,247
Other segment items [3] 6,447 5,653
Interest income, net (3,602) (4,748)
Net loss $ 47,911 $ 29,065
[1] Includes expense related to the Company’s Human Abuse Potential study, the Company’s Phase 2a CANAL trial of Haduvio for the treatment of chronic cough in patients with IPF, and the Company’s Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis.
[2] Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.
[3] Includes general administrative expense, interest expense, net, other (expense) income, net and income tax benefit.